ADVANCES IN CAR T-CELL TREATMENT
L.W. Kwak, Duarte, CA (USA), et al.
Authors Conclusion from the abstract: Taken together, our data suggest that BAFF‐R is amenable to CAR T‐cell therapy and that targeting it may add to existing alternative strategies to overcome relapse from CD19 antigen loss, such as CD22 CAR T cells. Future strategies combining dual targeting of CD19 and BAFF‐R may also be effective.
C.L. Batlevi, New York, NY (USA), et al.
Authors Conclusion from the abstract: Treatment with 19‐28z/4‐1BBL armored CAR T cells is safe with no severe CRS. Grade 3 neurotoxicity was noted in 3 pt (11%) with no case of cerebral edema. The overall CR rate is 57% with 8 patients remaining in CR at the time of this report. Future studies are warranted to develop and improve on existing CAR T cell therapies.
C.A. Ramos, Houston, TX (USA), et al.
Authors Conclusion from the abstract: Twelve patients have been evaluated at 6 weeks after infusion. Seven have had a CR lasting up to >15 months, 1 had a partial response, and 4 had disease progression. In 2 patients who relapsed after CR and were re‐biopsied, immunohistochemistry evidenced persistent tumor expression of CD30. Hence, infusion of CD30.CARTs after cytoreductive chemotherapy is well tolerated at the doses used. Inclusion of cytoreduction pre‐infusion substantially improves CD30.CART expansion and appears associated with superior anti‐tumor activity in relapsed patients.
J. Gauthier, Seattle, WA (USA), et al.
Authors Conclusion from the abstract: In conclusion, CD19 CAR‐T cell therapy with concurrent ibrutinib for R/R CLL was feasible and led to high rates of durable responses, without ≥ grade 3 CRS.
A.V. Hirayama, Seattle, WA (USA), et al.
Authors Conclusion from the abstract: CD19 CAR‐T cell immunotherapy is highly effective in adults with clinically aggressive R/R FL, with durable CR in a high proportion of FL pts.
T. Siddiqi, Duarte, CA (USA), et al.
Authors Conclusion from the abstract: Based on preliminary results, the combination of liso‐cel with durvalumab has an acceptable safety profile. No CRS was observed after initiation of durvalumab. Preliminary data suggest CAR T cells persist and/or increase with combination treatment, warranting further clinical evaluation. Updated data will be presented.